The Role of Hypoxia as a Selective Pressure for TP53 Mutations
The study aims to develop scans that tell the investigators about the oxygen content of tumours using Magnetic Resonance Imaging (MRI) and seeing whether regions of low oxygen content are related to mutations in cancer genes such as TP53. MRI is a method of obtaining pictures of inside of the body that shows the appearance and structure of soft tissues.
To get the information about the oxygen content of tumours, MRI is carried out while breathing 100% oxygen. The variation of oxygen supply to different regions of the tumour will help the investigators to predict tumour behavior and tumour response to treatment.
調査の概要
状態
条件
詳細な説明
Cancer tissue harbours a multitude of genetic alterations, and it is well-established that when certain key alterations develop, they are powerful determinants of tumour behaviour (growth rate, potential to spread). One of the most sinister and well-recognized alterations is in a gene called TP53. Another feature of tumours that results in resistance to treatment and poor outcome is a low oxygen level within tumour tissue. However, whether alterations in TP53 are driven by low oxygen levels is not established.
Endometrial cancer is a good model to study the relationship between low tumour oxygen levels and alterations in TP53 within tumour. Firstly, it is a common gynaecological malignancy, (9,300 new cases annually in the UK) with two recognized types based on the appearance and behaviour of the tumour. In type I (endometrioid and mucinous carcinomas), alterations in TP53 are uncommon (15%), while in type II (serous and clear cell carcinomas) they are common (88%). In-line with this, the survival of patients with Type 2 cancer is worse. Secondly, endometrial cancer is routinely assessed at diagnosis using Magnetic Resonance Imaging. This non-invasive scanning technique can be manipulated to derive additional information about the oxygen status of the whole tumour and regions within it. Finally, the primary management of endometrial cancer is surgical and involves hysterectomy. This means it is possible to obtain fresh tumour tissue at the time of surgery from regions that have been identified on imaging as having low vs.high levels of oxygen and to establish their TP53 status. In this study, therefore, the investigator will establish the regional oxygen distribution within endometrial cancers at diagnosis, and relate them to the alterations in TP53 from fresh tissue samples from selected regions using gene sequencing. Understanding how highly deleterious mutations arise in cancer might provide new avenues for intervention and control.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Surrey
-
Sutton、Surrey、イギリス、SM2 5PT
- The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- ≥18 years of age on the day of signing the informed consent.
- Histologically confirmed endometroid or serous endometrial cancer.
- Scheduled to have hysterectomy at the cancer centre
- Identifiable tumour mass on staging MRI.
- Voluntarily agreed to participate by giving written informed consent.
Exclusion Criteria:
- Life expectancy of < 6 months.
- Ferromagnetic implants, contraindicating MRI
- Claustrophobia so unable to tolerate MRI
- Unable to lie flat
- Ascites sufficient to prevent patient being fitted in the scanner bore
- Histology unlikely to show variation in TP53 status, or heavily calcified disease.
- Radiotherapy to the abdomen or pelvis within 6 months of the screening visit.
- Unresolved bowel obstruction.
- Currently participating or has participated in a study with an investigational compound or device within 30 days of the start of treatment.
- History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
- Unlikely to comply with the requirements of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Endometriod
Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
|
|
Serous
Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Establish distinctive patterns of distribution and expression of mutant TP53 between tumour regions with differing levels of oxygenation (as measured by R2*on MRI).
時間枠:Duration of study (24 months)
|
Determined at post surgery histology
|
Duration of study (24 months)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The reproducibility of the R2* measurement, assessed by comparing 2 R2* scans per person
時間枠:6 months
|
comparison of image data at conclusion of MRI scan
|
6 months
|
|
Establish the range of intratumoral heterogeneity of the R2* measurement within individual tumours
時間枠:6 months
|
comparison of image data at conclusion of MRI scan
|
6 months
|
協力者と研究者
捜査官
- 主任研究者:Nandita deSouza、The Institution of Cancer Research & The Royal Marsden NHS Foundation Trust
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CCR 4784
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。